Arterra Bioscience (ARBS) H1 2026 earnings summary

Executive summary

• Revenue for H1 2026 reached €3.03M, up 18% year-over-year, driven by higher sales of cosmetic raw materials, research services, and capital contributions from funded projects.

• Net profit for H1 2026 was €742K, compared to €319K in H1 2025, reflecting improved operating performance, though some sources report a decline from €1.09M in H1 2025.

• The company distributed €977K in dividends from the previous year's profit.

• Equity as of June 30, 2026, stood at €12.35M, slightly down due to dividend distribution and compared to €12.6M at year-end 2025.

• The company remains optimistic about achieving full-year targets, with early H2 2026 sales continuing the positive trend.

Financial highlights

• Total production value rose to €3.47M from €3.14M in H1 2025.

• Operating costs increased to €2.46M, mainly due to higher personnel and service expenses.

• EBITDA margin remained strong, with a difference between production value and costs of €1.02M.

• Cash and cash equivalents at period end were €1.31M.

• Total assets as of June 30, 2026: €14.6M.

Outlook and guidance

• Strong order backlog and H1 growth, along with early H2 sales, support optimism for achieving 2026 growth targets.

• Ongoing advanced research projects are expected to deliver innovative products to market in the near future.